LPCN vs. IGMS, INCR, IMUX, ICCC, BMEA, STRO, ADAP, SKYE, IKNA, and CLSD
Should you be buying Lipocine stock or one of its competitors? The main competitors of Lipocine include IGM Biosciences (IGMS), InterCure (INCR), Immunic (IMUX), ImmuCell (ICCC), Biomea Fusion (BMEA), Sutro Biopharma (STRO), Adaptimmune Therapeutics (ADAP), Skye Bioscience (SKYE), Ikena Oncology (IKNA), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry.
Lipocine vs. Its Competitors
IGM Biosciences (NASDAQ:IGMS) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.
In the previous week, IGM Biosciences had 4 more articles in the media than Lipocine. MarketBeat recorded 6 mentions for IGM Biosciences and 2 mentions for Lipocine. IGM Biosciences' average media sentiment score of 0.46 beat Lipocine's score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the media.
Lipocine has higher revenue and earnings than IGM Biosciences. Lipocine is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks.
IGM Biosciences has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500.
42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Lipocine has a net margin of 0.00% compared to IGM Biosciences' net margin of -7,417.79%. Lipocine's return on equity of -26.68% beat IGM Biosciences' return on equity.
IGM Biosciences currently has a consensus price target of $5.50, suggesting a potential upside of 305.90%. Lipocine has a consensus price target of $9.00, suggesting a potential upside of 175.23%. Given IGM Biosciences' higher probable upside, research analysts plainly believe IGM Biosciences is more favorable than Lipocine.
Summary
Lipocine beats IGM Biosciences on 9 of the 16 factors compared between the two stocks.
Get Lipocine News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipocine Competitors List
Related Companies and Tools
This page (NASDAQ:LPCN) was last updated on 7/5/2025 by MarketBeat.com Staff
Free LPCN Stock Alerts